Our data strongly suggest that YJ1206, as an oral CDK12/13 degrader, may serve as a promising candidate for combination therapy with AKT pathway inhibitors, offering an avenue for the effective treatment of prostate cancer. This evidence concerns the gene CDK12 and prostate carcinoma.